GeoVax to Present at Vaccines Summit-2022
October 11 2022 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, today announced that Senior Scientist
Sreenivasa Oruganti, Ph.D., will present at the Vaccines
Summit-2022 taking place October 11-13, 2022, in Reston, VA.
Dr. Oruganti will discuss the challenges surrounding emerging
COVID-19 variants of concern, T-cell responses to COVID-19 proteins
and GeoVax’s COVID-19 vaccine, GEO-CM04S1, currently in two Phase 2
clinical trials for the treatment of immunocompromised patients and
as a booster vaccine for healthy patients who have already received
an mRNA vaccine.
Details of the presentation are as follows:Title: “Design and
Evaluation of MVA-Vectored Universal Betacoronavirus
Vaccines”Session: Coronavirus (COVID-19) Vaccine ResearchDate and
Time: Wednesday, October 12, 9:00-9:20 a.m. ETLocation: Sheraton
Reston Hotel, Room B
“GeoVax’s COVID-19 vaccine program represents next-generation
COVID-19 vaccines using proven MVA technology with the potential of
providing more robust and durable protection, including against
evolving variants,” said David Dodd, GeoVax Chairman and CEO.
“GEO-CM04S1 is a next-generation, multi-antigen vaccine,
targeting conserved viral proteins and inducing both antibody and
T-cell/cellular immunity. The vaccine has the potential to offer
unprecedented protection to immunocompromised populations such as
those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient. GEO-CM04S1 may also serve as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines.”
GeoVax is also evaluating a second pan-coronavirus vaccine,
GEO-CM02. Currently in preclinical small animal studies, GEO-CM02
offers the potential of a single-dose, universal coronavirus
vaccine without the traditional requirements of a highly
refrigerated/frozen state, able to be distributed and administered
as needed worldwide.
For more information about the Vaccines Summit-2022, please
visit the event webpage here.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines and immunotherapies against infectious
diseases and cancer using novel proprietary platforms. GeoVax’s
product pipeline includes two ongoing Phase 2 clinical trials of
GEO-CM04S1 for COVID-19 as a universal booster vaccine to mRNA
vaccines authorized by the U.S. Food and Drug Administration (FDA)
and as a primary vaccine for use in immunocompromised patients. In
addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02
as a pan-coronavirus vaccine. The Company is also conducting a
Phase 1/2 clinical trial of Gedeptin® for treatment of head and
neck cancer. Gedeptin® has been granted orphan drug status by the
FDA. Additional research and development programs include
preventive vaccines against Zika Virus, hemorrhagic fever viruses
(Ebola, Sudan, Marburg, and Lassa) and malaria, as well as
immunotherapies for multiple solid tumors. The Company’s portfolio
of wholly owned, co-owned, and in-licensed intellectual property
stands at 115 granted or pending patent applications spread over 24
patent families.
For additional information about GeoVax, visit our website:
www.geovax.com.
Media Relations Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Apr 2023 to Apr 2024